Gabapentin Sustained-Release (Gralise) Dosing and Administration
Gralise should be titrated to 1,800 mg taken once daily with the evening meal, swallowed whole without crushing, splitting, or chewing, and must be dose-adjusted for renal impairment (contraindicated if CrCl <30 mL/min or on hemodialysis). 1
Titration Schedule
The target dose of 1,800 mg once daily should be achieved through gradual titration. 1 While the FDA label does not specify exact titration steps for Gralise, the general principle for gabapentin formulations is to start low and increase by 100-300 mg every 1-7 days as tolerated. 2 This cautious approach minimizes dose-dependent side effects like dizziness and sedation. 2
Critical Administration Requirements
Food Requirement
- Gralise MUST be taken with the evening meal to optimize absorption. 1
- Taking Gralise on an empty stomach substantially reduces bioavailability—food increases Cmax by 33-84% and AUC by 33-118% depending on fat content. 1
- The gastroretentive formulation is designed to remain in the stomach for prolonged periods, gradually releasing gabapentin to enhance absorption via saturable transporters. 3, 4
Tablet Integrity
- Tablets must be swallowed whole—do not crush, split, or chew. 1
- The gastroretentive technology requires intact tablets to function properly. 3
Renal Dose Adjustments
Dose adjustment is mandatory in renal impairment because gabapentin is eliminated entirely by renal excretion as unchanged drug. 1
Specific Renal Dosing:
- CrCl ≥60 mL/min: Standard dosing (1,800 mg once daily) 1
- CrCl 30-59 mL/min: Dose reduction required 1
- CrCl <30 mL/min: Gralise should NOT be used 1
- Hemodialysis patients: Gralise is contraindicated—consider alternative gabapentin formulations 1
The rationale is clear: as renal function declines, gabapentin clearance decreases proportionally, leading to prolonged half-life (from 5-7 hours in normal function to 40 hours when CrCl <30 mL/min). 1 In hemodialysis patients, the half-life extends to approximately 132 hours on non-dialysis days. 1
Discontinuation and Tapering
When reducing, discontinuing, or substituting Gralise, taper gradually over a minimum of 1 week or longer to minimize withdrawal risk. 1 The Mayo Clinic guidelines emphasize that dose reduction should be performed more cautiously than titration. 5
Important Precautions
Age-Related Considerations
- Elderly patients require dose adjustments due to age-related decline in renal function. 1
- Apparent oral and renal clearances decrease with age, necessitating lower doses. 1
High-Risk Populations for Adverse Events
Even with appropriate dosing, certain patients face increased risk of gabapentinoid-related adverse events (GRAEs):
- Older age (mean age 66 vs 61 years for those with GRAEs) 6
- History of seizures (14% with GRAEs vs 3% without) 6
- Concomitant antipsychotic use (24% with GRAEs vs 5% without) 6
These patients warrant closer monitoring, as GRAEs are associated with significantly longer hospital stays (8.5 vs 5.3 days). 6
Common Pitfalls to Avoid
Do not substitute Gralise for other gabapentin products—the once-daily gastroretentive formulation has different pharmacokinetics than immediate-release gabapentin (which requires three-times-daily dosing). 1
Do not prescribe without assessing renal function—inappropriate dosing in CKD patients is common (45% in one study) and increases adverse event risk. 6
Do not allow patients to take on empty stomach—this defeats the purpose of the gastroretentive formulation and dramatically reduces efficacy. 1
Do not abruptly discontinue—withdrawal symptoms can occur without proper tapering. 5, 1
Expected Timeline for Efficacy
The once-daily Gralise formulation may provide analgesia more quickly than immediate-release gabapentin due to optimized absorption, though an adequate trial still requires 3-8 weeks for titration plus 2 weeks at maximum dose. 2 The gastroretentive delivery system maintains more stable plasma levels compared to immediate-release formulations. 3, 7